Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

Research and Innovation Action · Running

SANGUINE Early detection and screening of hematological malignancies

Coordinator
Tel Aviv University, Israel
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€8.5m
Total cost
€8.5m
Partners
11 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101097026

What the project is doing

In the project's own words, from its summary on CORDIS.

Project SANGUINE addresses the objectives raised by the Cancer Mission Call, which emerged from the growing societal challenge faced by European citizens. According to the European Cancer Information System (ECIS), each year, 2.7 million people in the EU are diagnosed with cancer. The SANGUINE project focuses on hematological malignancies, which account for 10% of those cases, and aims to target the four objectives of the Cancer Mission: (1) understanding, (2) prevention, including screening and early detection, (3) diagnosis, and (4) quality of life improvement of the patients and their relatives.

The project introduces a novel minimally-invasive blood test that detects and classifies a set of hematological malignancies. The test is based on detecting a combination of epigenetic biomarkers in DNA from peripheral blood cells and in cell-free DNA. The SANGUINE test will provide superior sensitivity at low-cost which is ideal for screening purposes. This is enabled by direct fluorescent labeling of epigenetic marks in patient DNA and its analysis on a custom designed microarray – the HemaChip.

SANGUINE team consists of a comprehensive and strong team of expert that will address medical, technological and social aspects of the developed diagnostic test. Expertise from the medical field includes clinical research, technology development and access to patients. This will enable optimization of the test for hematological malignancies following a user-centric approach and experiencing its implementation in “real-life” clinical settings.

The social part of the team includes researchers and patient organization that will promote accessibility of the test to patients and individuals at-risk for screening, early detection and disease management, in combination with a study aiming to increase the screening rates. Ultimately, our project will provide validated reagents, HemaChips and data analysis software ready for large scale screening and early stage commercialization.

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator
European Cancer OrganisationBruxelles / BrusselBelgiumParticipant
Fakultni Nemocnice OlomoucOlomoucCzechiaParticipant
Univerzita Palackeho V OlomouciOlomoucCzechiaParticipant
Fzmb GmbH Forschungszentrum Fur Medizintechnik Und BiotechnologieBad LangensalzaGermanyParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Predictby Research and Consulting S.l.BarcelonaSpainParticipant
Jaxbio Technologies LtdPardes Hanna-KarkurIsraelParticipant
The Foundation for Medical Research Infrastructural Development and Health Services Next to the Medical Center Tel AvivTel AvivIsraelParticipant
Uab OrientosVilniusLithuaniaParticipant
Vilniaus Universiteto Ligonine Santaros KlinikosVilniusLithuaniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI